Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05735327
Status:
RECRUITING
Last Update Posted:
2023-09-05
First Post:
2023-02-10
Brief Title:
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer NSCLC ENTIRETY
Sponsor:
Takeda
Organization:
Takeda
Organization Data
Organization:
Takeda
Class:
INDUSTRY
Study ID:
Brigatinib-4004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Takeda
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None